Treatment
Î The AGA recommends using linaclotide (over no drug
treatment) in patients with IBS-C. Strong; High Quality of
Evidence
Comments: Patients who place a high value on avoiding diarrhea and avoiding
higher out-of-pocket expenses associated with linaclotide may prefer alternate
treatments.
Î The AGA suggests using lubiprostone (over no drug treatment)
in patients with IBS-C. Conditional; Moderate Quality of
Evidence
Comments: Patients who place a high value on avoiding higher out-of-pocket
expenses associated with lubiprostone may prefer alternate treatments.
Î The AGA suggests using laxatives (over no drug treatment) in
patients with IBS-C. Conditional; Low Quality of Evidence
Î The AGA suggests using rifaximin (over no drug treatment) in
patients with IBS-D. Conditional; Moderate Quality of Evidence
Î The AGA suggests using alosetron (over no drug treatment) in
patients with IBS-D to improve global symptoms. Conditional;
Moderate Quality of Evidence
Î The AGA suggests using loperamide (over no drug treatment)
in patients with IBS-D. Conditional; Very Low Quality of
Evidence
Î The AGA suggests using tricyclic antidepressants (over no
drug treatment) in patients with IBS. Conditional; Low Quality
of Evidence
Î The AGA suggests against using selective serotonin reuptake
inhibitors for patients with IBS. Conditional; Low Quality of
Evidence
Î The AGA suggests using antispasmodics (over no drug
treatment) in patients with IBS. Conditional; Low Quality of
Evidence
AGA Institute Guidelines on the Pharmacological Management of Irritable Bowel Syndrome
